Moderna on Thursday asked the Food and Drug Administration to authorize a lower-dose version of its COVID-19 vaccine for children younger than 6 years old.

Sources said if, by chance, FDA approves the two-dose treatment, Moderna’s immunizations could become the first available to some of America’s youngest residents — who have been mostly unprotected during the years-long coronavirus pandemic.

At the moment, only those ages 5 and older are eligible to be vaccinated, leaving about 18 million all but exposed to the fast-spreading disease.

“We are proud to share that we have submitted for authorization for our COVID-19 vaccine for young children,” said Stéphane Bancel, Moderna’s chief executive officer, in a statement.

“We believe [the vaccine] will be able to safely protect these children against SARS-CoV-2, which is so important in our continued fight against COVID-19, and will be especially welcomed by parents and caregivers,” Bancel added in the same statement.

The move of Moderna came as a response to the call for many families for a shot that would be available for some of the littlest in the nation.

Last month, Moderna revealed that its COVID-19 vaccine for younger children generated a strong immune response.

In testing the treatment among two groups — 6 months old to 23 months old as well as 2 years old to under 6 years old — researchers saw a “robust neutralizing antibody response” and a “favorable safety profile.”

Moderna said the shots proved between 40% and 50% effective at preventing symptomatic COVID-19 during the trial, and there were no severe side effects.

JOIN US ON WHAT'SAPP, TO GET INSTANT STATUS UPDATES AND BE IN THE KNOW.

CLICK HERE

bobby bracros

Author bobby bracros

More posts by bobby bracros

Leave a Reply